Art that unites everyone. Health of Ukraine. Thematic number. December 2015

On November 5-6, 2015, at the Ukrainian House, was held a biennial entitled "Diagnosis: Artist" within the framework of the All-Ukrainian Project "Uniting All!" , where paintings of patients of psychiatric hospitals were displayed together with paintings by famous Ukrainian artists. The organizers of this project are the Ukrainian Research Institute of Social and Forensic Psychiatry and Addiction of the Ministry of Health of Ukraine and the Association of Psychiatrists of Ukraine. The event was supported by the Lithuanian pharmaceutical company Farmlyga and the Lithuanian Embassy. The purpose of the biennale was to demonstrate the creative potential of people with mental health disabilities and to draw public attention to the needs of these people and the importance of integrating them into society.

The Ministry of Health of Ukraine is grateful to Farmlyga

Farmlyga as a socially responsible company received a letter of thanks from the Ministry of Health of Ukraine for providing charitable assistance to maternity hospitals in Ukraine in the form of 6,500 packages of Proginorm Gesta 100mg м30 in the amount of more than 2 million hryvnias. As part of social projects at the national level, Farmlyga plans to continue charitable activities for hospitals of various profiles.

Viacheslav Volodymyrovych Kaminskiy

Full Professor and Head of Department of Obstetrics, Gynaecology and Reproductology, National Medical Academy of Postgraduate Education (NMAPE); Chief of Executive Committee of Association of Obstetricians and Gynaecologists of Ukraine (AOGU) Executive Committee of the Association of Obstetricians and Gynecologists of Ukraine

Current approaches in the treatment of pregnancy miscarriage

Posted by: В.В. Kaminskyi, V.V. Konoplianko, M.N. Shalko, N.Ya. Ratushniak Department of Obstetrics, Gynecology and Reproductology of the NMAPE named after P.L. Shupyk Kyiv City Center for Reproductive and Perinatal Medicine. Publication Place: Reproductive Health. Eastern Europe. 2018, Volume 8, №1. Summary: The article presents the results of the study of the effectiveness of the drug Proginorm OVO and Proginorm GESTA in the schemes of complex therapy of the threat of termination of pregnancy and the threat of premature birth. 290 pregnancies with the risk of interruption or the risk of preterm birth were analyzed at different times. Women groups were representative of age, parity, place of residence, social status, and somatic health status. the efficacy in the treatment regimen of the oral form of natural micronized progesterone Proginorm OVO 100 mg, 200mg and vaginal form Progestin GESTA 100 mg, 200mg with individual selection of therapeutic dose from 200mg to...

Micronized progesterone in the prevention and treatment of pregnancy miscarriage.

Posted by: I.I. Vorobіova, S.M. Tolkach, V.B. Tkachenko,A.A. Zhyvetska-Denysova, N.V. Rudakova. Institute of Pediatrics, obstetrics and gynecology named after Academician О. M. Lukyinic NAMS of Ukraine Place of publication: Reproductive Health. Eastern Europe. 2019, Volume 9, № 3.     Summary: Pregnancy miscarriage is one of the major medical and social problems in obstetric practice, perinatal medicine and public health in general. The great importance and widespread use of progesterone during pregnancy have led scientists to invent a new, highly effective, bioavailable and easy to use a form of this hormone - micronisation. The results of the work proved that the clinical use, according to the indications, of these forms of progestins during pre-gravidar drug and the direct course of pregnancy is an effective means of prevention and treatment of certain forms of miscarriage. As micronized progesterone, the drugs Proginorm GESTA and Proginorm OVO, adapted for, respectively, vaginal and oral...

ІНФОРМАЦІЙНИЙ ЛИСТ про нововведення в системі охорони здоров’я № 293 - 2018 Нові терапевтичні підходи у лікуванні невиношування вагітності

Випуск з проблеми «Акушерство та гінекологія» Підстава: Рішення ВР НМАПО ім.. П.Л. Шупика МОЗ України Протокол № 3 від 20.09.2018 р. ГОЛОВНОМУ АКУШЕРУ-ГІНЕКОЛОГУ ДЕПАРТАМЕНТУ ОХОРОНИ ЗДОРОВ’Я ОБЛАСНИХ ТА КИЇВСЬКОЇ МІСЬКОЇ ДЕРЖАВНИХ АДМІНІСТРАЦІЙ. УСТАНОВИ-РОЗРОБНИКИ: НАЦІОНАЛЬНА МЕДИЧНА АКАДЕМІЯ ПІСЛЯДИПЛОМНОЇ ОСВІТИ ім. П.Л. Шупика УКРМЕДПАТЕНТІНФОРМ МОЗ УКРАЇНИ. АВТОРИ: Член-кореспондент НАМН України, д. мед. н., професор КАМІНСЬКИЙ В.В., к. мед. н., доцент КОНОПЛЯНКО В.В., к. мед. н., ШАЛЬКО М.Н., РАТУШНЯК Н.Я. Прогинорм ГЕСТА та Прогинорм ОВО запропоновано до впровадження в лікувально-профілактичних установах практичної охорони здоров’я (обласних, міських, районних) акушерсько-гінекологічного профілю. Прогинорм ГЕСТА та Прогинорм ОВО мають доведену ефективність, забезпечують стійкий, високий терапевтичний ефект, добре переносяться, сприяють більш короткому періоду перебування в стаціонарі вагітної жінки. Надійний ефект при використанні як оральної, так і вагінальної форми мікронізованого прогестерону. Отримані результати лікування відповідають середньостатистичним показникам у країнах ЄС. Прогинорм ГЕСТА та Прогинорм ОВО можуть бути рекомендовані для використання в широкій акушерській практиці, особливо з огляду на їх...

Premenstrual syndrome. Pathogenetic aspects of treatment

Posted by: Т.F. Tatarchuk,  Doctor of Medical Sciences (MD), Full Professor, Associate Member of the National Academy of Medical Sciences of Ukraine,  Doctor of Medical Sciences (MD), N.F. Zakharenko, I.P. Manoliak. Place of publication: Reproductive Endocrinology № 5 (43) November 2018. Summary: The purpose of the study described in the article was to study the effectiveness of the use of micronized progesterone in the treatment of the premenstrual syndrome. 68 women of reproductive age from 18 to 40 years (mean age 31.2 ± 5.3 years) with the premenstrual syndrome of mild and moderate severity were examined. The study women were randomized into two groups: treatment group (n = 35) and control group (n = 33). Study groups were matched for age and forms of premenstrual syndrome. The patients in the treatment group received treatment with Proginorm OVO 200 mg daily for 16 to 25 days of the menstrual cycle for...

Treatment and prevention of obstetric and perinatal complications in pregnant women with uterine leiomyoma.

Posted by: H.B. Semenyna, H.Yu. Fedoriv, 1. Danylo Halytsky Lviv National Medical University (Department of Obstetrics and Gynecology, Head of the Department Doctor of Medical Sciences, Professor, Member of NAMS of Ukraine, Honored Worker of Science and Technology of Ukraine Leonid Borysovych Markin), 2. Lviv Regional Clinical Hospital. Place of publication: Reproductive Health. Eastern Europe. 2018, Volume 8, № 4.

New dosage forms of micronized progesterone - the basis for the correction of the reproductive problems of the female body

Posted by: V.V. Bobritskaya, Kharkiv Medical Academy of Postgraduate Education, Kharkiv, Ukraine. Publication: Reproductive Health. Eastern Europe. 2017, Volume 7, No 4. Summary: The data of an analytical review of the effectiveness of the use of micronized progesterone in various clinical situations are presented: from the beginning of the reproductive period to menopause. According to international consensus, vaginal forms of micronized progesterone are defined as the most effective (along with injectable dosage forms) in cases of threatened preterm birth, habitual miscarriage, in assisted reproductive technology programs. Oral and vaginal dosage forms are recommended in the presence of menstrual irregularities, accompanied by luteal phase insufficiency, the menopausal period in the hormone replacement therapy complex. The new generation micronized progesterone Proginorm Gest for vaginal use and Proginorm OVO for oral use, at a dosage of 100 and 200 mg, are optimal drugs that fully comply with the requirements of domestic and international...

Farmlyga participation in the IV Scientific and Practical Conference with International Involvement «Advances in Neurology».

On October 15-17, 2020, Farmlyga, the Lithuanian company, participated in one of the largest neurological conferences «Advances in Neurology». More than 2,000 practicing neurologists, pediatric neurologists and doctors of related specialties, listened to the presentations of the leading specialists from USA, Germany, Denmark and Ukraine.